Atmosphere-ph.ru

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru

ИНТЕРНЕТ-МАГАЗИН

Лечебное дело
2019 / N 4

Хроническая болезнь почек у лиц пожилого и старческого возраста: факторы риска и возможности ранней диагностики
И.Т. Муркамилов

Список литературы

1. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии 2019;16(1):6-31.
2. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет 2017;20(1):13-41.
3. Бойцов С.А., Зайратьянц О.В., Андреев Е.М., Самородская И.В. Сравнение показателей смертности от ишемической болезни сердца среди мужчин и женщин старше 50 лет в России и США. Российский кардиологический журнал 2017;22(6):100-7.
4. Авдеев С.Н. Патофизиология обострений хронической обструктивной болезни легких. Вестник анестезиологии и реаниматологии 2019;16(2):75-82.
5. Odden MC, Shlipak MG, Whitson HE, Katz R, Kearney PM, Shastri S, Sarnak MJ, Siscovick DS, Cushman M, Psaty BM, Newman AB. Risk factors for cardiovascular disease across the spectrum of older age: the cardiovascular health study. Atherosclerosis2014Nov;237(1):336-42.
6. Голубев А.Г. Почему мы стареем и как? – один ответ на два вопроса. Успехи геронтологии 2018;31(4):458-72.
7. Анисимов В.Н., Серпов В.Ю., Финагентов А.В., Хавинсон В.Х. Новый этап развития геронтологии и гериатрии в России: проблемы создания системы гериатрической помощи. Часть 2. Структура системы, научный подход. Успехи геронтологии 2017;30(4):486-97.
8. Айтбаев К.А., Муркамилов И.Т., Фомин В.В. Молекулярные механизмы старения: роль окислительного стресса и эпигенетических модификаций. Успехи геронтологии 2019;32(1-2):20-8.
9. McClure M, Jorna T, Wilkinson L, Taylor J. Elderly patients with chronic kidney disease: do they really need referral to the nephrology clinic? Clinical Kidney Journal 2017 Oct;10(5):698-702.
10. Reher D, Requena M. Living alone in later life: a global perspective. Population and Development Review 2018 Apr;44(3):427-54.
11. Aucella F, Corsonello A, Leosco D, Brunori G, Gesualdo L, Antonelli-Incalzi R. Beyond chronic kidney disease: the diagnosis of renal disease in the elderly as an unmet need. A position paper endorsed by Italian Society of Nephrology (SIN) and Italian Society of Geriatrics and Gerontology (SIGG). Journal of Nephrology 2019 Apr;32(2):165-76.
12. Лебедев А.А., Пузин С.Н., Потапов В.Н., Шургая М.А. От геронтологии к медицине антистарения. Медико-социальная экспертиза и реабилитация 2014;2:4-6.
13. Вишневский А.Г. Похвала старению. Отечественные записки 2005;3:78-96.
14. Сафарова Г.Л., Косолапенко Н.Г., Арутюнов В.А. Региональная дифференциация показателей старения населения России. Успехи геронтологии 2005;16(1):7-13.
15. Голубев А.Г. Биохимия продления жизни. Успехи геронтологии2003;12:57-76.
16. Фомин В.В., Милованов Ю.С., Милованова Л.Ю., Моисеев С.В., Мухин Н.А. Хроническая болезнь почек у пожилых: особенности диагностики и ведения. Клиническая нефрология 2014;3:3-7.
17. Белоусов Ю.Б., Леонова М.В. Особенности применения лекарств в гериатрической практике. Фарматека 2008;8:13-9.
18. Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Advances in Chronic Kidney Disease 2016 Jan;23(1):19-28.
19. Glassock RJ, Rule AD. Aging and the kidneys: anatomy, physiology and consequences for defining chronic kidney disease. Nephron 2016;134(1):25-9.
20. Vogel SL. Urinary incontinence in the elderly. Ochsner Journal 2001Oct;3(4):214-8.
21. Паскалев Д.Н. Инфекции мочевыводящих путей в пожилом возрасте: некоторые медицинские аспекты. Нефрология 2003;7(4):7-13.
22. Ranson RN, Saffrey MJ. Neurogenic mechanisms in bladder and bowel ageing. Biogerontology 2015 Apr;16(2):265-84.
23. Vlase HL, Panagopoulos G, Michelis MF. Effectiveness of furosemide in uncontrolled hypertension in the elderly: role of renin profiling. American Journal of Hypertension 2003Mar;16(3):187-93.
24. Горелик С.Г., Мудраковская Э.В., Колпакова Н.А. Характерные особенности хронических прогрессирующих нефропатий в пожилом и старческом возрасте. Фундаментальные исследования 2012;7:283-8.
25. Остроумова О.Д., Кочетков А.И., Черняева М.С. Артериальная гипертензия у пациентов пожилого и старческого возраста в свете новых Европейских рекомендаций 2018 года. Рациональная фармакотерапия в кардиологии 2018;14(5):774-84.
26. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). The European Heart Journal 2018Sep;39(33):3021-104.
27. Ратова Л.Г., Чазова И.Е. Изолированная систолическая артериальная гипертония. Кардиоваскулярная терапияи профилактика 2007;6(2):93-104.
28. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001 Mar;103(9):1245-9.
29. Шабалин А.В., Воевода М.И. Гериатрические аспекты кардиологии. Новосибирск: Наука;2003.156 с.
30. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. European Heart Journal 2006 Nov;27(21):2588-605.
31. Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation 1997 Jul;96(1):308-15.
32. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrology, Dialisis, Transplantation 2000 Jul;15(7):1014-21.
33. Forette B. Hypertension in very old subjects. Clinical and Experimental Hypertension (New York, N.Y.: 1993) 1999 Jul-Aug;21(5-6):917-25.
34. Langer R, Ganiats Т, Barrett-Connor E. Paradoxical survival of elderly man with high blood pressure. BMJ 1989 May;298(6684):1356-7.
35. Mattila K, Haavisto M, Rajala S, Heikinheimo R. Blood pressure and five year survival in the very old.BMJ1988Mar;296(6626):887-9.
36. Преображенский Д.В. Артериальная гипертония у пожилых: особенности у патогенеза и лечения. Клиническая геронтология 2006;10:3-13.
37. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler J A, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. The New England Journal of Medicine 2015;373(22):2103-16.
38. Benetos A, Buatois S, Salvi P, Marino F, Toulza O, Dubail D, Manckoundia P, Valbusa F, Rolland Y, Hanon O, Gautier S, Miljkovic D, Guillemin F, Zamboni M, Labat C, Perret-Guillaume C. Blood pressure and pulse wave velocity values in the institutionalized elderly aged 80 and over: baseline of the PARTAGE study. Journal of Hypertension 2010 Jan;28(1):41-50.
39. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Boehm M, Galderisi M. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). The European Heart Journal 2013;34:2159-219.
40. Oganov RG, Simanenkov VI, Bakulin IG, Bakulina NV, Barbarash OL, Boytsov SA, Bolduyeva SA, Garganeyeva NP, Doshchitsin VL, Karateyev AE, Kotovskaya YuV, Lila AM, Lukyanov MM, Morozova TE, Pereverzev AP, Petrova MM, Pozdnyakov YuM, Syrov AV, Tarasov AV, Tkacheva ON, Shalnova SA. Comorbidities in clinical practice. Algorithms for diagnosis and treatment. Cardiovascular Therapy and Prevention 2019;18(1):5-66 (In Russian).
41. Муркамилов И.Т., Сабиров И.С., Айтбаев К.А., Фомин В.В., Муркамилова Ж.А., Сабирова А.И., Раимжанов З.Р., Реджапова Н.А., Юсупов Ф.А., Айдаров З.А. Почечная дисфункция и показатели артериальной жесткости у лиц пожилого и старческого возраста. Успехи геронтологии 2018;31(4):549-55.
42. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Makaroff LE. IDF Diabetes Atlas. Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice 2017Jun;128:40-50.
43. Шамхалова М.Ш., Викулова О.К., Железнякова А.В., Исаков М.А., Шестакова М.В., Дедов И.И. Эпидемиология хронической болезни почек в Российской Федерации по данным федерального регистра взрослых пациентов с сахарным диабетом (2013-2016 гг.). Сахарный диабет2018;21(3):160-9.
44. Carretero Gómez J, Arévalo Lorido JC. Clinical assessment and treatment of diabetes in patients with chronic kidney disease. Revista Clinica Espanola 2018 Aug-Sep;218(6):305-15.
45. Alsahli M, Gerich J. Hypoglycemia in patients with diabetes and renal disease.Journal of Clinical Medicine 2015 May;4(5):948-64.
46. Betônico CC, Titan SM, Correa-Giannella ML, Nery M, Queiroz M. Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control. Clinics (Sao Paulo, Brasil) 2016 Jan;71(1):47-53.
47. Tandogdu Z, Wagenlehner FME. Global epidemiology of urinary tract infections. Current Opinion in Infectious Diseases 2016 Feb;29(1):73-9.
48. Elwali ES, Almobarak AO, Hassan MA, Mahmooud AA, Awadalla H, Ahmed MH. Frequency of diabetic retinopathy and associated risk factors in Khartoum, Sudan: population based study. International Journal of Ophthalmology 2017;10(6):948-54.
49. Wingard DL, Sinsheimer P, Barrett-Connor EL, McPhillips JB. Community-based study of prevalence of NIDDM in older adults. DiabetesCare1990Feb;12(Suppl3):3-8.
50. Пронина Е.А. Сахарный диабет второго типа в гериатрической практике. Сибирское медицинское обозрение 2013;6:92-7.
51. Oh SW, Kim YC, Koo HS, Jin DC, Na KY, Chae DW, Kim S, Chin HJ. Glycated haemoglobin and the incidence of end-stage renal disease in diabetics. Nephrology, Dialysis, Transplantation 2011 Jul;26(7):2238-44.
52. Neumiller JJ, Hirsch IB. Management of hyperglycemia in diabetic kidney disease. Diabetes Spectrum 2015 Aug;28(3):214-9.
53. Neumiller JJ, Hirsch IB. Glycemic metrics and targets in kidney disease. In: Endocrine disorders in kidney disease. Diagnosis and treatment. Rhee SM, Kalantar-Zadeh K, Brent GA, editors. Cham, Switzerland: Springer; 2019: 39-48.
54. Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vascular Health and Risk Management 2008;4(3):575-96.
55. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 2008 Jun;358(24):2560-72.
56. Барсуков А.В., Таланцева М.С., Свеклина Т.С., Багаева З.В., Зобнина М.П. Гиполипидемическая терапия у пожилых пациентов. В фокусе статины и прогноз. Артериальная гипертензия 2011;17(5):415-24.
57. American Heart Association. Older Americans and cardiovascular diseases statistics. 2004. Available at: http://www.americanheart.org/downloadi-theart/1136584495498OlderAm06.pdf Accessed 2019 Dec 12.
58. Aronow WS, Frishman WH. Management of hyperholesterinemia in older persons for the prevention of cardiovascular disease. Cardiology in Review 2010 May-Jun;13(3):132-40.
59. Shao H, Chen LQ, Xu J. Treatment of dyslipidemia in the elderly.Journal of Geriatric Cardiology2011 Mar;8(1):55-64.
60. Rovin BH, Tan LC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney International 1993 Jan;43:218-25.
61. Keane WF, O’Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low-density lipoproteins by mesangial cells. Journal of the American Society of Nephrology 1993 Aug;4(2):187-94.
62. Kume S, Uzu T, Araki SI, Sugimoto T, Isshiki K, Chin-Kanasaki M, Sakaguchi M, Kubota N, Terauchi Y, Kadowaki T, Haneda M, Kashiwagi A,Koya D. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. Journal of the American Society of Nephrology 2007 Oct;18(10):2715-23.
63. Colina IB. Hyperlipidemia in patients with chronic kidney disease: features and approaches to treatment. The Attending Physician 2012;1:63-70.
64. Chen CY, Lee CW, Chien SC, Su MI, Lin SI, Cheng CW, Yeh HI. Dyslipidemia management for elderly people with metabolic syndrome: a mini-review. International Journal of Gerontology 2018 Mar;12(1):7-11.
65. Tonelli MA, Wanner C. Kidney Disease. Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney International Supplements 2013 Nov;3(3):1-315.
66. Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. The American Journal of Cardiology 1996 Apr;77(10):864-6.
67. Corti MC, Guralnik JM, Salive ME, Harris T, Ferrucci L, Glynn RJ, Havlik RJ. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Annals of Internal Medicine 1997 May;126(10):753-60.
68. Reuben DB, Ix JH, Greendale GA, Seeman TE. The predictive value of combined hypoalbuminemia and hypocholesterolemia in high functioning community-dwelling older persons: MacArthur studies of successful aging. Journal of the American Geriatrics Society 1999 Apr;47(4):402-6.
69. Рекомендации ЕОК/ЕОА по диагностике и лечению дислипидемий 2016. Российский кардиологический журнал 2017;22(5):7-77.
70. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. The Lancet 2011 Jun;377(9784):2181-92.
71. Gränsbo K, Melander O, Wallentin L, Lindbäck J, Stenestrand U, Carlsson J, Nilsson J. Cardiovascular and cancer mortality in very elderly post-infarction patients receiving statin treatment. Journal of the American College of Cardiology2010 Mar;55(13):1362-9.
72. Aronow WS, Ahn C, Gutstein H. Incidence of new atherothrombotic brain infarction in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol≥ 125 mg/dL treated with statins versus no lipid-lowering drug. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2002 May;57(5):M333-5.
73. Алиджанова Х.Г., Ржевская О.Н., Сагиров М.А., Газарян Г.А. Прогностическое значение хронической болезни почек у больных с острым коронарным синдромом. Неотложная медицинская помощь.Журнал им. Н.В. Склифосовского2017;6(2):132-9.
74.Mizuiri S, Nishizawa Y, Yamashita K, Mizuno K, Ishine M, Doi S, Shigemoto K. Coronary artery calcification score and common iliac artery calcification score in non‐dialysis CKD patients. Nephrology (Carlton, Vic.) 2018 Sep;23(9):837-45.
75.Pickup L, Radhakrishnan A, Townend J N, Ferro CJ. Arterial stiffness in chronic kidney disease: a modifiable cardiovascular risk factor? Current Opinion in Nephrology and Hypertension 2019 Nov;28(6):527-36.
76.Pergola PE, Fishbane S, Ganz T. Novel oral iron therapies for iron deficiency anemia in chronic kidney disease. Advances in Chronic Kidney Disease 2019 Jul;26(4):272-91.
77.Patel ML, Sachan R, Singh GP, Chaudhary SC, Gupta KK, Atam V, Parihar A. Assessment of subclinical atherosclerosis and endothelial dysfunction in chronic kidney disease by measurement of carotid intima media thickness and flow-mediated vasodilatation in North Indian population. Journal of Family Medicine and Primary Care 2019 Apr;8(4):1447-52.
78. Kiu Weber CI, Duchateau-Nguyen G, Solier C, Schell-Steven A, Hermosilla R, Nogoceke E, Block G. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal 2014 Apr;7(2):167-73.
79. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal 2014 Oct;35(37):2541-619.
80. Sittichanbuncha Y, Sricharoen P, Tangkulpanich P, Sawanyawisuth K. The appropriate troponin T level associated with coronary occlusions in chronic kidney disease patients. Therapeutics and Clinical Risk Management 2015;11:1143-7.
81. Koppe L, Fouque D. The role for protein restriction in addition to renin-angiotensin-aldosterone system inhibitors in the management of CKD. American Journal of Kidney Diseases 2019 Feb;73(2):248-57.
82. Leon SJ, Tangri N. The use of renin-angiotensin-inhibitors in patients with chronic kidney disease. The Canadian Journal of Cardiology 2019 Sep;35(9):1220-7.
83. Pavkov ME, Nelson RG. Estimating GFR in the elderly – new approaches to an old problem. Kidney International Reports 2019 Jun;4(6):763-5.
84. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. American Journal of Kidney Diseases 2002 Aug;40(2):221-6.
85. Grubb A, Nyman U, Björk J, Lindström V, Rippe B, Sterner G, Christensson A. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clinical Chemistry 2005 Aug;51(8):1420-31.
86. Grubb A, Björk J, Lindström V, Sterner G, Bondesson P, Nyman U. A cystatin C‐based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft‐Gault formula. Scandinavian Journal of Clinical and Laboratory Investigation 2005;65(2):153-62.
87. Короленко Т.А. Цистатины–биологическая роль и нарушения в патологии. Вестник РАМН 2008;4:43-7.
88. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Critical Reviews in Clinical Laboratory Sciences 2004;41(5-6):467-550.
89. Mares J, Stejskal D, Vavrouskova J, Urbánek K, Herzig R, Hluštík P, Krejčí K. Use of cystatin C determination in clinical diagnostics. Biomedical Papers of the Medical Faculty of the of the University Palacky, Olomouc, Czech Republic 2003 Dec;147(2):177-80.
90. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. American Journal of Kidney Disease 2001 Jan;37(1):79-83.
91. Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrology, Dialisis, Transplantation 2006 Jul;21(7):1855-62.
92. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Annals of Internal Medicine 2006 Aug;145(4):237-46.
93. Hall A, Håkansson K, Mason RW, Grubb A, Abrahamson M. Structural basis for the biological specificity of cystatin C. Identification of leucine 9 in the N-terminal binding region as a selectivity-conferring residue in the inhibition of mammalian cysteine peptidases. The Journal of Biological Chemistry 1995 Mar;270(10):5115-21.
94. Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, Satterfield S, Cummings SR, Newman AB, Fried LF. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. Journal of the American Society of Nephrology 2006 Jan;17(1):254-61.
95. Randers E, Kristensen H, Erlandsen EJ, Danielsen S. Serum cystatin C as a marker of the renal function. Scandinavian Journal of Clinical and Laboratory Investigation 1998 Nov;58(7):585-92.
96. Shlipak MG, Praught ML, Sarnak MJ. Update on cystatin C: new insights into the importance of mild kidney dysfunction. Current Opinion in Nephrology and Hypertension 2006 May;15(3):270-5.
97. Jernberg T, Lindahl B, James S, LarssonA, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004 Oct;110(16):2342-8.
98. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clinical Chemistry 2005 Feb;51(2):321-7.
99. Muntner P, Mann D, Winston J, Bansilal S, Farkouh ME. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. The American Journal of Cardiology 2008 Jul;102(1):54-7.
100. Муркамилов И.Т., Сабиров И.С., Фомин В.В., Муркамилова Ж.А., Айтбаев К.А., Райимжанов З.Р. Оценка нефроцеребрального риска с использованием цистатина С у больных хронической болезнью почек. Журнал неврологии и психиатрии им. С.С. Корсакова 2018;118(9):10-6.
101. Муркамилов И.Т., Фомин В.В., Айтбаев К.А., Муркамилова Ж.А., Сабиров И.С. Содержание цистатина С плазмы крови и его взаимосвязь с аугментационным индексом и центральным артериальным давлением у пациентов терапевтического профиля. Клиническая нефрология 2018;3:31-40.
102. Bevc S, Hojs N, Knehtl M, Ekart R, Hojs R. Cystatin C as a predictor of mortality in elderly patients with chronic kidney disease. The Aging Male 2019 Mar;22(1):62-7.
103. Canney M, Sexton DJ, O’Leary N, Healy M, Kenny RA, Little MA, O’Seaghdha CM. Examining the utility of cystatin C as a confirmatory test of chronic kidney disease across the age range in middle-aged and older community-dwelling adults. Journal of Epidemiology and Community Health 2018 Apr;72(4):287-93.
104. Duque GC, Passos MT, Nishida SK, Sabino ARP, Kirsztajn GM. Assessment of glomerular filtration rate in older adults in Brazil. Journal of Nephrology and Urology2017 Jan;1(1):4.
105. Abboud O, Adler S, Bertram K. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International. Supplement 2013 Jan;3(1):1-150.

References

1. Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension 2019;16(1):6-31 (In Russian).
2. Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry. Diabetes Mellitus 2017;20(1):13-41 (In Russian).
3. Boytsov SA, Zayratyants OV, Andreyev EM, Samorodskaya IV. Comparison of coronary heart disease mortality in men and women over 50 years of age in Russia and USA. Russian Journal of Cardiology 2017;(6):100-7 (In Russian).
4. Avdeyev SN. Pathologic physiology of exacerbations of chronic obstructive pulmonary disease. Messenger of Anesthesiology and Resuscitation 2019;16(2):75-82 (In Russian).
5. Odden MC, Shlipak MG, Whitson HE, Katz R, Kearney PM, Shastri S, Sarnak MJ, Siscovick DS, Cushman M, Psaty BM, Newman AB. Risk factors for cardiovascular disease across the spectrum of older age: the cardiovascular health study. Atherosclerosis 2014 Nov;237(1):336-42.
6. Golubev AG. Why do we age and how? – one answer to two questions. Advances in Gerontology 2018;4(31):458-72 (InRussian).
7. Anisimov VN, Serpov VYu, Finagentov AV, Khavinson VKh. A new stage of gerontology and geriatrics development in Russia: problems of creating system of geriatric care. Part 2.The structure of the system, scientific approach. Advances in Gerontology 2017;30(4):486-97 (In Russian).
8. Aytbayev KA, Murkamilov IT, Fomin VV. Molecular mechanisms of aging: role of oxidative stress and epigenetic modifications. Advances in Gerontology 2019;32(1-2):20-8 (In Russian).
9. McClure M, Jorna T, Wilkinson L, Taylor J. Elderly patients with chronic kidney disease: do they really need referral to the nephrology clinic? Clinical Kidney Journal 2017 Oct;10(5):698-702.
10. Reher D, RequenaM. Living alone in later life: a global perspective. Population and Development Review 2018 Apr;44(3):427-54.
11. Aucella F, Corsonello A, Leosco D, Brunori G, Gesualdo L, Antonelli-Incalzi R. Beyond chronic kidney disease: the diagnosis of renal disease in the elderly as an unmet need. A position paper endorsed by Italian Society of Nephrology (SIN) and Italian Society of Geriatrics and Gerontology (SIGG). Journal of Nephrology 2019 Apr;32(2):165-76.
12. Lebedev AA, Puzin SN, Potapov VN, ShurgayaМА. From gerontology to anti-aging medicine. Medical and Social Expert Evaluation and Rehabilitation 2014;2:4-6 (In Russian).
13. Vishnevskiy AG. Praiseto aging. Otechestvennye Zapiski 2005;3:78-96 (In Russian).
14. Safarova GL, Kosolapenko NG, Arutyunov VA. Regional differentiation of ageing indicators in Russia. Advances in Gerontology 2005;16(1):7-13 (In Russian).
15. Golubev AG. Biochemistry of life extension. Advances in Gerontology 2003;12:57-76 (InRussian).
16. Fomin VV, Milovanov YuS, YuMilovanova LYu, Moiseyev SV, Mukhin NA. Chronic kidney disease in elderly: diagnosis and management. Clinical Nephrology 2014;3:3-7 (In Russian).
17. BelousovYuB, Leonova MV. Use of drugs in geriatric practice. Farmateka 2008;8:13-9 (In Russian).
18. Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Advances in Chronic Kidney Disease 2016 Jan;23(1):19-28.
19. Glassock RJ, Rule AD. Aging and the kidneys: anatomy, physiology and consequences for defining chronic kidney disease. Nephron 2016;134(1):25-9.
20. Vogel SL. Urinary incontinence in the elderly. Ochsner Journal 2001 Oct;3(4):214-8.
21. Paskalev DN. Urinary tract infections in elderly: some medical aspects. Nephrology (Saint-Petersburg) 2003;7(4):7-13 (In Russian).
22. Ranson RN, Saffrey MJ. Neurogenic mechanisms in bladder and bowel ageing. Biogerontology 2015 Apr;16(2):265-84.
23. Vlase HL, Panagopoulos G, Michelis MF. Effectiveness of furosemide in uncontrolled hypertension in the elderly: role of renin profiling. American Journal of Hypertension 2003 Mar;16(3):187-93.
24. Gorelik SG, Mudrakovskaya EV, Kolpakova NA. Feachures of chronic progressive nephropathies in elderly and older age. Fundamental Research 2012;7:283-8 (In Russian).
25. Ostroumova OD, Kochetkov AI, Chernayeva MS. Arterial hypertension in elderly and senile patients in the light of New European Guidelines 2018. Rational Pharmacotherapy in Cardiology 2018;14(5):774-84 (In Russian).
26. Williams B, Mancia G, Spiering W, AgabitiRosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). The European Heart Journal 2018 Sep;39(33):3021-104.
27. Ratova LG, Chazova IE. Isolated systolic arterial hypertension. Cardiovascular Therapy and Prevention 2007;6(2):93-104(In Russian).
28. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001 Mar;103(9):1245-9.
29. Shabalin AV, Voyevoda MI. Geriatric aspects of cardiology. Novosibirsk: Nauka 2003.156 p. (In Russian).
30. Laurent S, Cockcroft J, VanBortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. European Heart Journal 2006 Nov;27(21):2588-605.
31. Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation 1997 Jul;96(1):308-15.
32. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrology, Dialisis, Transplantation 2000 Jul;15(7):1014-21.
33. Forette B. Hypertension in very old subjects. Clinical and Experimental Hypertension (New York, N.Y.: 1993) 1999 Jul-Aug;21(5-6):917-25.
34. Langer R, GaniatsТ, Barrett-Connor E. Paradoxical survival of elderly man with high blood pressure. BMJ 1989 May;298(6684):1356-7.
35. Mattila K, Haavisto M, Rajala S, Heikinheimo R. Blood pressure and five year survival in the very old. BMJ 1988 Mar;296(6626):887-9.
36. Preobrazhenskiy DV. Arterial hypertension in the elderly: pathogenesis and treatment. Clinical Gerontology 2006;10:3-13 (In Russian).
37. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, CutlerJ A, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. The New England Journal of Medicine 2015;373(22):2103-16.
38. Benetos A, Buatois S, Salvi P, Marino F, Toulza O, Dubail D, Manckoundia P, Valbusa F, Rolland Y, Hanon O, Gautier S, Miljkovic D, Guillemin F, Zamboni M, Labat C, Perret-Guillaume C. Blood pressure and pulse wave velocity values in the institutionalized elderly aged 80 and over: baseline of the PARTAGE study. Journal of Hypertension 2010 Jan;28(1):41-50.
39. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Boehm M, Galderisi M. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). The European Heart Journal 2013;34:2159-219.
40. Oganov RG, Simanenkov VI, Bakulin IG, Bakulina NV, Barbarash OL, Boytsov SA, Bolduyeva SA, Garganeyeva NP, Doshchitsin VL, Karateyev AE, Kotovskaya YuV, Lila AM, Lukyanov MM, Morozova TE, Pereverzev AP, Petrova MM, Pozdnyakov YuM, Syrov AV, Tarasov AV, Tkacheva ON, Shalnova SA. Comorbidities in clinical practice. Algorithms for diagnosis and treatment. Cardiovascular Therapy and Prevention 2019;18(1):5-66 (In Russian).
41. Murkamilov IT, Sabirov IS, Aytbayev KA, Fomin VV, Murkamilova ZhA, Sabirova AI, Rayimzhanov ZR, Redjapova NA, Yusupov FA, Aydarov ZA. Renal dysfunction and indicators of arterial hormity in persons of elderly and senile age. Advances in Gerontology 2018;31(4):549-55 (In Russian).
42. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Makaroff LE. IDF Diabetes Atlas. Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice 2017 Jun;128:40-50.
43. Shamkhalova MS, Vikulova OK, Zheleznyakova AV, Isakov MA, Shestakova MV, Dedov II. Epidemiology of chronic kidney disease in Russian Federation according to the federal diabetes register (2013-2016). Diabetes Mellitus 2018;21(3):160-9 (In Russian).
44. Carretero Gómez J, Arévalo Lorido JC. Clinical assessment and treatment of diabetes in patients with chronic kidney disease. Revista Clinica Espanola 2018 Aug-Sep;218(6):305-15.
45. Alsahli M, Gerich J. Hypoglycemia in patients with diabetes and renal disease. Journal of Clinical Medicine 2015 May;4(5):948-64.
46. Betônico CC, Titan SM, Correa-Giannella ML, Nery M, Queiroz M. Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control. Clinics (Sao Paulo, Brasil) 2016 Jan;71(1):47-53.
47. Tandogdu Z, Wagenlehner FME. Global epidemiology of urinary tract infections. Current Opinion in Infectious Diseases 2016 Feb;29(1):73-9.
48. Elwali ES, Almobarak AO, Hassan MA, Mahmooud AA, AwadallaH, Ahmed MH. Frequency of diabetic retinopathy and associated risk factors in Khartoum, Sudan: population based study. International Journal of Ophthalmology 2017;10(6):948-54.
49. Wingard DL, Sinsheimer P, Barrett-Connor EL, McPhillips JB. Community-based study of prevalence of NIDDM in older adults.DiabetesCare 1990 Feb;12(Suppl 3):3-8.
50. Pronina EA. Type 2 diabetes in geriatric practice. Siberian Medical Review 2013;6:92-7 (In Russian).
51. Oh SW, Kim YC, Koo HS, Jin DC, Na KY, Chae DW, Kim S, Chin HJ. Glycated haemoglobin and the incidence of end-stage renal disease in diabetics. Nephrology, Dialysis, Transplantation 2011 Jul;26(7):2238-44.
52. Neumiller JJ, Hirsch IB. Management of hyperglycemia in diabetic kidney disease. Diabetes Spectrum 2015 Aug;28(3):214-9.
53. Neumiller JJ, Hirsch IB. Glycemic metrics and targets in kidney disease. In: Endocrine disorders in kidney disease. Diagnosis and treatment. Rhee SM, Kalantar-Zadeh K, Brent GA, editors. Cham, Switzerland: Springer; 2019: 39-48.
54. Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vascular Health and Risk Management 2008;4(3):575-96.
55. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 2008 Jun;358(24):2560-72.
56. Barsukov AV, Talantseva MS, Sveklina TS, Bagayeva ZV, Zobnina MP. Lipid-lowering therapy in elderly patients. The focus is on statins and the prognosis. Arterial Hypertension 2011;17(5):415-24 (In Russian).
57. American Heart Association. Older Americans and cardiovascular diseases statistics. 2004. Available at: http://www.americanheart.org/downloadi-theart/1136584495498OlderAm06.pdf Accessed 2019 Dec 12.
58. Aronow WS, Frishman WH. Management of hyperholesterinemia in older persons for the prevention of cardiovascular disease. Cardiology in Review 2010 May-Jun;13(3):132-40.
59. Shao H, Chen LQ, Xu J. Treatment of dyslipidemia in the elderly.Journal of Geriatric Cardiology 2011 Mar;8(1):55-64.
60. Rovin BH, Tan LC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney International 1993 Jan;43:218-25.
61. Keane WF, O’Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low-density lipoproteins by mesangial cells. Journal of the American Society of Nephrology 1993 Aug;4(2):187-94.
62. Kume S, Uzu T, Araki SI, Sugimoto T, Isshiki K, Chin-Kanasaki M, Sakaguchi M, Kubota N, Terauchi Y, Kadowaki T, Haneda M, Kashiwagi A, Koya D. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. Journal of the American Society of Nephrology 2007 Oct;18(10):2715-23.
63. Colina IB. Hyperlipidemia in patients with chronic kidney disease: features and approaches to treatment. The Attending Physician 2012;1:63-70.
64. Chen CY, Lee CW, Chien SC, Su MI, Lin SI, Cheng CW, Yeh HI. Dyslipidemia management for elderly people with metabolic syndrome: a mini-review. International Journal of Gerontology 2018 Mar;12(1):7-11.
65. Tonelli MA, Wanner C. Kidney Disease. Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney International Supplements 2013 Nov;3(3):1-315.
66. Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. The American Journal of Cardiology 1996 Apr;77(10):864-6.
67. Corti MC, Guralnik JM, Salive ME, Harris T, Ferrucci L, Glynn RJ, Havlik RJ. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Annals of Internal Medicine 1997 May;126(10):753-60.
68. Reuben DB, Ix JH, Greendale GA, Seeman TE. The predictive value of combined hypoalbuminemia and hypocholesterolemia in high functioning community-dwelling older persons: MacArthur studies of successful aging. Journal of the American Geriatrics Society 1999 Apr;47(4):402-6.
69. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman JМ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccard G, Taskinen M, Tokgozoglu L, Verschuren W, Vlachopoulos C, Wood DА, Zamorano JL, Cooney M. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Russian Journal of Cardiology 2017;22(5):7-77 (In Russian).
70. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. The Lancet 2011 Jun;377(9784):2181-92.
71. Gränsbo K, Melander O, Wallentin L, Lindbäck J, Stenestrand U, Carlsson J, Nilsson J. Cardiovascular and cancer mortality in very elderly post-infarction patients receiving statin treatment. Journal of the American College of Cardiology 2010 Mar;55(13):1362-9.
72. Aronow WS, Ahn C, Gutstein H. Incidence of new atherothrombotic brain infarction in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol≥ 125 mg/dL treated with statins versus no lipid-lowering drug. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2002 May;57(5):M333-5.
73. Alidzhanova KhG, Rzhevskaya ON, Sagirov MA, Gazaryan GA. Prognostic value of chronic kidney disease in patients with a cute coronary syndrome. NV Sklifosofskiy Journal of Emergency Medical Care 2017;6(2):132-9 (In Russian).
74. Mizuiri S, Nishizawa Y, Yamashita K, Mizuno K, Ishine M, Doi S, Shigemoto K. Coronary artery calcification score and common iliac artery calcification score in non‐dialysis CKD patients. Nephrology (Carlton, Vic.) 2018 Sep;23(9):837-45.
75. Pickup L, Radhakrishnan A, Townend J N, Ferro CJ. Arterial stiffness in chronic kidney disease: a modifiable cardiovascular risk factor? Current Opinion in Nephrology and Hypertension 2019 Nov;28(6):527-36.
76. Pergola PE, Fishbane S, Ganz T. Novel oral iron therapies for iron deficiency anemia in chronic kidney disease. Advances in Chronic Kidney Disease 2019 Jul;26(4):272-91.
77. Patel ML, Sachan R, Singh GP, Chaudhary SC, Gupta KK, Atam V, Parihar A. Assessment of subclinical atherosclerosis and endothelial dysfunction in chronic kidney disease by measurement of carotid intima media thickness and flow-mediated vasodilatation in North Indian population. Journal of Family Medicine and Primary Care 2019 Apr;8(4):1447-52.
78. Kiu Weber CI, Duchateau-Nguyen G, Solier C, Schell-Steven A, Hermosilla R, Nogoceke E, Block G. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal 2014 Apr;7(2):167-73.
79. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal 2014 Oct;35(37):2541-619.
80. Sittichanbuncha Y, Sricharoen P, Tangkulpanich P, Sawanyawisuth K. The appropriate troponin T level associated with coronary occlusions in chronic kidney disease patients. Therapeutics and Clinical Risk Management 2015;11:1143-7.
81. Koppe L, Fouque D. The role for protein restriction in addition to renin-angiotensin-aldosterone system inhibitors in the management of CKD. American Journal of Kidney Diseases 2019 Feb;73(2):248-57.
82. Leon SJ, Tangri N. The use of renin-angiotensin-inhibitors in patients with chronic kidney disease. The Canadian Journal of Cardiology 2019 Sep;35(9):1220-7.
83. Pavkov ME, Nelson RG. Estimating GFR in the elderly – new approaches to an old problem. Kidney International Reports 2019 Jun;4(6):763-5.
84. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. American Journal of Kidney Diseases 2002 Aug;40(2):221-6.
85. Grubb A, Nyman U, Björk J, Lindström V, Rippe B, Sterner G, Christensson A. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clinical Chemistry 2005 Aug;51(8):1420-31.
86. Grubb A, Björk J, Lindström V, Sterner G, Bondesson P, Nyman U. A cystatin C‐based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft‐Gault formula. Scandinavian Journal of Clinical and Laboratory Investigation 2005;65(2):153-62.
87. Korolenko TA. Cystatins – biological role and disorders in pathology. Herald of the Russian Academy of Medical Sciences 2008;4:43-7 (In Russian).
88. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Critical Reviews in Clinical Laboratory Sciences 2004;41(5-6):467-550.
89. Mares J, Stejskal D, Vavrouskova J, Urbánek K, Herzig R, Hluštík P, Krejčí K. Use of cystatin C determination in clinical diagnostics. Biomedical Papers of the Medical Faculty of the of the University Palacky, Olomouc, Czech Republic 2003 Dec;147(2):177-80.
90. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. American Journal of Kidney Disease 2001 Jan;37(1):79-83.
91. Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrology, Dialisis, Transplantation 2006 Jul;21(7):1855-62.
92. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Annals of Internal Medicine 2006 Aug;145(4):237-46.
93. Hall A, Håkansson K, Mason RW, Grubb A, Abrahamson M. Structural basis for the biological specificity of cystatin C. Identification of leucine 9 in the N-terminal binding region as a selectivity-conferring residue in the inhibition of mammalian cysteine peptidases. The Journal of Biological Chemistry 1995 Mar;270(10):5115-21.
94. Shlipak MG, WasselFyr CL, Chertow GM, Harris TB, Kritchevsky SB,Tylavsky FA,Satterfield S,Cummings SR, Newman AB, Fried LF. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. Journal of the American Society of Nephrology 2006 Jan;17(1):254-61.
95. Randers E, Kristensen H, Erlandsen EJ, Danielsen S. Serum cystatin C as a marker of the renal function. Scandinavian Journal of Clinical and Laboratory Investigation 1998 Nov;58(7):585-92.
96. Shlipak MG, Praught ML, Sarnak MJ. Update on cystatin C: new insights into the importance of mild kidney dysfunction. Current Opinion in Nephrology and Hypertension 2006 May;15(3):270-5.
97. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004 Oct;110(16):2342-8.
98. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clinical Chemistry 2005 Feb;51(2):321-7.
99. Muntner P, Mann D, Winston J, Bansilal S, Farkouh ME. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. The American Journal of Cardiology 2008 Jul;102(1):54-7.
100. Murkamilov IT, Sabirov IS, Fomin VV, MurkamilovaZhA, Aytbayev KA, Rayimzhanov ZR. Assessment of nephrocerebral risk by cystatin C in patients with chronic kidney disease. SS Korsakov Journal of Neurology and Psychiatry 2018;118(9):10-6 (In Russian).
101. Murkamilov IT, Fomin VV, Aytbayev KA, Murkamilova ZhA, Sabirov IS. Cystatin C from blood plasma and its relationship with the augmentation index and central arterial pressure in patients with a therapeutic profile. Clinical Nephrology 2018;3:31-40 (In Russian).
102. Bevc S, Hojs N, Knehtl M, Ekart R, Hojs R. Cystatin C as a predictor of mortality in elderly patients with chronic kidney disease. The Aging Male 2019 Mar;22(1):62-7.
103. Canney M, Sexton DJ, O’Leary N, Healy M, Kenny RA, Little MA, O’Seaghdha CM. Examining the utility of cystatin C as a confirmatory test of chronic kidney disease across the age range in middle-aged and older community-dwelling adults. Journal of Epidemiology and Community Health 2018 Apr;72(4):287-93.
104. Duque GC, Passos MT, Nishida SK, Sabino ARP, Kirsztajn GM. Assessment of glomerular filtration rate in older adults in Brazil. Journal of Nephrology and Urology 2017 Jan;1(1):4.
105. Abboud O, Adler S, Bertram K. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International. Supplement 2013 Jan;3(1):1-150.

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]